This bill revises the FDA’s user fee program for over-the-counter (OTC) monograph drugs, extending it through fiscal year 2030 and adjusting how fees are calculated, due, and used. It also broadens the regulatory framework for nonprescription drugs and adds a new testing-procedure standard tied to voluntary consensus standards recognized by the Secretary.
The package includes a sunset and savings provisions to ensure periodic reauthorization and updated governance of the program.
At a Glance
What It Does
The bill authorizes and reorganizes OTC monograph facility fees and OTC monograph order request fees, sets new applicable periods for fee assessment (2026–2030), and updates due dates for these fees.
Who It Affects
OTC monograph drug facilities (fee-paying entities), sponsors or requestors of OTC monograph orders, organizations representing those sponsors, and FDA program staff administering the OTC monograph program.
Why It Matters
It secures funding for regulatory oversight of OTC monograph drugs, modernizes testing practice via recognized voluntary standards, and provides a framework for periodic reauthorization and updates.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill overhauls the funding mechanism for FDA’s oversight of OTC monograph drugs. It redefines the timing and amount of facility fees and order-request fees, establishing a new multi-year schedule that runs from fiscal year 2026 through 2030 and detailing when those fees are due.
The revenue mix includes a base amount, an inflation adjustment, and an operating-reserve component, plus adjustments tied to annual costs and a potential one-time workload adjustment for certain years. Importantly, the bill adds a concrete mechanism to support testing procedures for OTC monograph drugs that reflect an established voluntary consensus standard for pharmaceutical quality, recognized by the Secretary through FDA guidance.
Section 5 updates reporting and reauthorization, and the sunset provisions in Section 7 cap the authority after October 1, 2030, with related fiscal-year reporting ending January 31, 2031. The effective date is set to October 1, 2025, with fees under the OTC monograph program beginning as specified, ensuring a staged transition from the prior regime.
The bill also expands the regulatory framework for nonprescription drugs marketed without an approved drug application by allowing sponsor/requestor organizations to nominate representatives to participate in proceedings, broadening industry input into regulatory decisions.
The Five Things You Need to Know
The bill extends the OTC monograph user fee program through FY 2030 with a revised fee schedule and due dates.
It adds a new testing procedure standard for OTC monograph drugs that aligns with recognized voluntary consensus standards.
It restructures fee revenues with base amounts, inflation adjustments, operating reserves, and a potential one-time workload adjustment.
It sunsets the authority in 2030, with a 2031 sunset-related reporting end date for related provisions.
It expands oversight of nonprescription drugs by permitting nominated organizations to represent sponsors or requestors in regulatory proceedings.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings
Section 2 characterizes the program’s purpose by tying the OTC monograph fee structure to the broader regulatory goals for ensuring drug quality and safety. It reinforces that the fees collected are dedicated to OTC monograph activities, signaling stable funding for ongoing regulatory work.
Definitions
Section 3 expands the FD&C Act to include a new testing-procedure trigger: if a testing procedure for OTC monograph drugs reflects a voluntary consensus standard recognized by the Secretary through FDA guidance, it can be adopted or modified. This anchors testing in externally recognized standards and ties FDA acceptance to formal guidance.
Authority to Assess and Use OTC Monograph Fees
Section 4 revises fee types (facility fees and order-request fees), sets new applicable periods for fee assessments, and defines updated due dates across fiscal years 2026–2030. It also conditions eligibility for certain fees on meeting timing and activity criteria, ensuring the mechanism aligns with agency budgeting needs.
Reauthorization; Reporting Requirements
Section 5 extends the authorization and updates reporting timelines, replacing references to CARES Act procedures with Over-the-Counter Monograph Drug User Fee Amendments terminology. It aligns reporting cadence with the revised fiscal-year framework and clarifies that reporting continues through 2030–2031 as part of the sunset process.
Regulation of Nonprescription Drugs Marketed Without an Approved Drug Application
Section 6 expands FDA’s regulatory reach by updating advisory language around development advice to sponsors/requestors and allowing organizations nominated by sponsors or requestors to represent their interests in regulatory proceedings. This broadens stakeholder input in nonprescription drug reviews.
Sunset Dates
Section 7 provides an explicit sunset for sections 744L and 744M by October 1, 2030, with related termination of certain reporting duties on January 31, 2031. This creates a defined end point for the current regime and motivates a future reauthorization cycle.
Effective Date
Section 8 establishes the act’s amendments as take effect on October 1, 2025, or the enactment date, whichever is later, with fees under part 10 beginning October 1, 2025. This ensures a clear transition period from the prior framework.
Savings Clause
Section 9 preserves the prior fee regime for fiscal years before 2026, ensuring a transition window where existing authorities continue to apply to earlier years even as new authorities take effect.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- FDA’s OTC Monograph program staff gain a more stable funding stream and clearer authority to regulate OTC drugs.
- OTC monograph drug facilities gain a predictable funding mechanism tied to regulatory oversight.
- Sponsors or requestors and their nominated organizations receive formal channels for participation in proceedings, potentially reducing regulatory ambiguity.
- Industry trade groups and associations representing OTC manufacturers benefit from standardized fee structures and clearer timelines.
- Consumers may benefit indirectly from continued, funded oversight and testing standards for OTC products.
Who Bears the Cost
- OTC monograph drug facilities pay updated facility fees under the revised schedule.
- Sponsors or requestors incur order-request fees and potential organizational costs to participate in proceedings.
- Organizations nominated to represent sponsor/requestor interests may incur membership or compliance costs.
- FDA incurs administrative costs to implement the revised fee regime and expanded oversight.
Key Issues
The Core Tension
The central dilemma is balancing a reliable, adequately funded OTC monograph program with the industry’s need to manage costs and regulatory burden, all while ensuring that testing and quality standards remain current and enforceable as the program approaches sunset.
The bill tightens funding and oversight for OTC monograph drugs but introduces several tensions. The one-time workload adjustment and inflation-based fee increases create potential cost pressures for facilities, which could translate into higher product costs for consumers or tighter margins for manufacturers.
The sunset clause ensures periodic reassessment but also introduces a finite horizon during which program stability must be renewed, potentially creating planning frictions for firms and the agency alike. Expanding representation in nonprescription drug proceedings—while increasing stakeholder input—could raise the complexity and duration of regulatory processes.
These tensions require careful administrative design to preserve timely reviews while maintaining robust quality oversight.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.